Sanofi ( NASDAQ: SNY) has entered a share purchase agreement in relation to the sale of a 50% controlling stake in Opella, ...

Sanofi Consumer Healthcare India Limited ( ($IN:SANOFICONR) ) just unveiled an update. Sanofi Consumer Healthcare India ...

Sanofi and CD&R have signed a share purchase agreement for the sale of a 50% stake in the consumer health business.

Sanofi is closer to selling a 50% controlling stake in the consumer health business, Opella to private equity Clayton ...

The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere, Gilead and Ultragenyx secured ...

The company faced headwinds in the December 2024 quarter (Q4) as it reported a significant decline in earnings.

The company announced its Q4 results after-market hours. Its shares ended 0.4% higher on Thursday at ₹4,759.35 on the BSE.

Kuehne+Nagel supports Sanofi in multiple countries worldwide, including Hungary, the UK, and the UAE, by providing customised ...

Pursuant to Regulation 24 (A) if the SEBI (listing obligations and disclosure requirement ) Regulations, 2015, please find enclosed annual secretarial compliance report for the year ended December ...

Sanofi Consumer Healthcare India Q4 Results 2025 on 21 Feb, 2025: Revenue decreased by 20.53% YoY & profit decreased by 34.66% YoY, profit at ₹44.3 crore and revenue at ₹170.7 crore.

Sanofi's deep partnership with OpenAI could be a huge differentiating factor. Check out why I rate SNY stock a buy.